GSA Capital Partners LLP Invests $537,000 in Pulmonx Co. (NASDAQ:LUNG)

GSA Capital Partners LLP bought a new position in shares of Pulmonx Co. (NASDAQ:LUNG) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 64,771 shares of the company’s stock, valued at approximately $537,000. GSA Capital Partners LLP owned 0.17% of Pulmonx at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its stake in shares of Pulmonx by 4.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 35,720 shares of the company’s stock worth $332,000 after buying an additional 1,633 shares during the period. Sei Investments Co. raised its stake in shares of Pulmonx by 2.5% during the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after buying an additional 1,800 shares during the period. nVerses Capital LLC acquired a new position in shares of Pulmonx during the 3rd quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Pulmonx during the 2nd quarter worth approximately $37,000. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Pulmonx by 609.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after buying an additional 7,316 shares during the period. 91.04% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Pulmonx

In related news, General Counsel David Aaron Lehman sold 5,765 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $6.69, for a total transaction of $38,567.85. Following the transaction, the general counsel now owns 203,348 shares of the company’s stock, valued at approximately $1,360,398.12. This represents a 2.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Glendon E. French III sold 20,000 shares of the stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $6.52, for a total value of $130,400.00. Following the transaction, the director now directly owns 1,091,974 shares in the company, valued at approximately $7,119,670.48. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,351 shares of company stock worth $361,494. 5.70% of the stock is currently owned by company insiders.

Pulmonx Stock Down 2.0 %

Shares of NASDAQ:LUNG opened at $6.00 on Wednesday. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The business has a fifty day moving average of $7.16 and a two-hundred day moving average of $7.17. The stock has a market cap of $236.93 million, a P/E ratio of -4.08 and a beta of 0.68. Pulmonx Co. has a 52-week low of $5.46 and a 52-week high of $14.84.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $20.39 million during the quarter, compared to analysts’ expectations of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same period in the prior year, the business posted ($0.39) EPS. On average, research analysts expect that Pulmonx Co. will post -1.53 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on LUNG shares. Stifel Nicolaus reduced their target price on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Wells Fargo & Company reduced their price objective on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Finally, Canaccord Genuity Group increased their price objective on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.67.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.